Action HEMISPHERX BIOPHARMA, INC
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription
Instrument Inactif

Autres langues Hemispherx BioPharma, Inc Nyse

Actions

US42366C3016

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
AIM ImmunoTech Says Safety Evaluation of First Dose Level of Pancreatic Cancer Study Completed
AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
AIM Immunotech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
Challenges To Advance Notice Bylaws Are Spiking
AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
North American Morning Briefing : Stocks Seen -2-
AIM ImmunoTech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast
AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action AIM
  4. Action
  5. Actualités Hemispherx BioPharma, Inc
  6. Autres langues